Navigation Links
REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted
Date:8/12/2008

CUPERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY(R) and granted Priority Review. The FDA typically grants Priority Review to drug candidates that have the potential to demonstrate significant improvements compared to marketed products. The FDA goal for completing review of a drug with Priority Review status is six months from the date the application was submitted. The REMOXY NDA was submitted to the FDA by Pain Therapeutics on June 10, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"We are pleased that the NDA has been accepted and that REMOXY will receive Priority Review," stated James E. Brown, DVM, President and CEO of DURECT. "The abuse of pain medications is a widespread problem in this country and addressing that issue is clearly in the public interest. We're delighted that our ORADUR(TM) technology has enabled the development of REMOXY, an investigational drug that has the potential to be the first oxycodone on the market that deters common methods of abuse."

REMOXY is being developed by Pain Therapeutics (Nasdaq: PTIE) under license from DURECT, and Pain Therapeutics has, in turn, sublicensed the commercialization rights for this drug candidate to King Pharmaceuticals (NYSE:

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
2. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
3. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
4. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
5. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011  Thoratec (NASDAQ: THOR), a world leader in device-based ... failing hearts, said today it will be participating in ... Tuesday, December 13. Taylor C. Harris, Senior ... an update on the company, beginning at 10:15 a.m., ...
...  VolitionRX Limited (VNRX.OB), a life sciences company focused on ... it will issue US$1,110,000 worth of shares of its ... issuance is the final requirement of the Share Purchase ... June 2011) between ValiRx and Singapore Volition Pte Limited, ...
Cached Medicine Technology:VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement 2
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... WA April 18, 2014) Benaroya Research Institute ... research how blocking a particular molecule in metastatic breast ... the number of lung metastases. BRI scientists have found ... can shrink tumors by 60 - 80 percent and ... the lung. The $1.8 million five-year grant comes from ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... Oct. 15 One Heartland will host "S,more to Love", a ... Open House Lofts, NYC to benefit Birch Family Camp. , Celebrating ... (over 200 family members) from the 5 boroughs of NYC, along ... building at a camp facility located in the Hudson Valley. ...
... 15 The Longaberger Company is teaming up with the ... against breast cancer. As part of the "Crucial Catch" campaign ... players - in partnership with the American Cancer Society - ... feature players, coaches and referees wearing pink game apparel to ...
... TALLAHASSEE, Fla. -- A Florida State University College of Medicine ... Institutes of Health (NIH) totaling $2.4 million to continue her ... months. Amy Wetherby is director of the Autism Institute ... WORDS Project has screened children to identify early red flags ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... Oct. 15 Astrup Drug Inc. has announced ... (ECRS) point-of-sale retail automation suite in their 11 ... selected by Astrup Drug to seamlessly automate their ... convenience/fuel integration, warehousing, front-end inventory control, and centralized ...
... for Presentation Also Nominated for Prestigious Prize , ... nine abstracts based on research by a total of 15 ... doctors, researchers and psychological social workers will be featured this ... meeting in Atlanta. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/DC66439LOGO ...
Cached Medicine News:Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 3Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Astrup Drug Implements ECRS Retail Solution Suite to Address Diverse Business Requirements 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 3Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 4
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... The Pediatric Ankle Cryo/Cuff is specifically designed ... 7). Using a combination of controlled compression ... and pain. The Pediatric Ankle Cryo/Cuff is ... hemorrhagic episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff ...
... Air-Stirrup Plus combines the clinically proven ... wrap. In addition, a comprehensive instruction ... Plus and provides information on treatment ... ankle sprain management.,Each Air-Stirrup Ankle Brace ...
... Full Transportability: Innovative design allows ... plug in for therapy or when ... Controller: Choose the prophylactic method to ... or both simultaneously. ,Automatic Garment Detection: ...
Medicine Products: